Patients with cardiac disease: Changes observed through last decade in out-patient clinics

Table 3 Medical treatments in each registry

	1999	2009	P vaule
Antiplatelets	42.0% (41.6-42.4)	76.8% (75.2-78.4)	< 0.01
Diuretics	32.0% (31.8-32.2)	4.4% (4.39-4.41)	< 0.01
ACEI	30.2% (30.0-30.4)	43.6% (43.1-44.1)	< 0.01
Statins	27.0% (26.9-27.1)	65.1% (63.9-66.3)	< 0.01
CCB	27.8% (27.6-28.0)	36.7% (36.3-37.1)	< 0.01
Nitrates	25.0% (24.9-25.1)	26.3% (26.1-26.5)	0.06
Beta-blockers	22.2% (22.1-22.3)	44.6% (44.1-45.1)	< 0.01
Oral anticoagulants	17.5% (17.4-17.6)	27.0% (26.8-27.2)	< 0.01
ARB	11.1% (11.0-11.1)	38.6% (38.2-39.0)	< 0.01
Insulin	5.1% (5.09-5.10)	13.7% (13.6-13.8)	< 0.01
Oral antidiabetics	10.0% (9.9-10.1)	43.7% (43.2-44.2)	< 0.01

Data collected from CARDIOTENS registries, Spain. Data presented as percentages (99%CI). ACEI: Angiotensin converter-enzyme inhibitors; ARB: Angiotensin receptor blockers; CCB: Calcium channel blockers.